PI3Ks signaling pathway as a molecular target for glioblastoma therapy: a review
PI3Ks signaling pathway as a molecular target for glioblastoma therapy: a review
Glioblastoma (GBM) is the most common type of cancer of the central nervous system (CNS). It currently accounts for about 2% of diagnosed malignant tumors, with 296,000 new cases reported each year. The gold standard treatment consists of surgical resection, radiotherapy and adjuvant chemotherapy which increases patient survival by 15 months and few survive more than 5 years after diagnosis. New clinical and pre-clinical research aims to improve this prognosis by proposing the search for new drugs that act effectively in the elimination of cancer cells bypassing problems such as resistance to treatment. One of the promising therapeutic strategies in the treatment of GBM is the inhibition of the phosphatidylinositol 3-kinase (PI3Ks) pathway, which is closely related to the process of tumor carcinogenesis. This review sought to address the main scientific studies of synthetic or natural drug prototypes that target specific therapy co-directed to the PI3Ks pathway, against human glioblastoma.